INSIGHTS ON DRUG DEVELOPMENT

• Why Reshoring Is An Essential Strategy For ADC Supply Chain Security

  Biotechs reshoring their supply chains to Western regions to mitigate risk and improve reliability require experienced partners to effectively manage these complex transitions.

• Particles In High Concentration Biotherapeutics

  Examine advanced analytical solutions that detect, characterize, and mitigate particle formation in high-concentration biotherapeutics caused by protein aggregation and surfactant degradation.

• Microglia: Where We Came From And Where We Are Now

  Gain expert insights into the evolution of microglia research and the future of this field, including the innovative tools being developed to investigate the role of microglia in health and disease.

• Nitrosamine Testing: How To Ensure Regulatory Compliance, Product Safety

  Explore what nitrosamines are, why testing matters, and how we're able to deliver high-confidence solutions through advanced science and industry-leading expertise.

• A Universal Workflow Approach For Single Cell Mass Spectrometry Based Proteomics

  11/7/2025

  Learn about a streamlined workflow that improves reproducibility, reduces contamination, and simplifies single-cell proteomics with comparable results to FACS.

• Temperature Dependence On Reversed-Phase Separations

  7/17/2025

  Column temperature critically affects the reversed-phase separation of fatty acid-modified GLP-1 RAs and impurities. Learn how precise control enhances resolution and reproducibility.

• MicroCoat™ Technology DFor Taste-Masking Amodiaquine, Artesunate In Oral Antimalarial Formulations

  1/14/2026

  Drive forward the development and adoption of taste‑masked ASAQ micropellets so children in low‑resource settings can receive life‑saving antimalarial treatment that is both effective and easy to take.

• Column Selection For RPLC-UV Impurity Analysis

  7/17/2025

  Explore the performance of four column chemistries for RPLC-UV impurity analysis of liraglutide and semaglutide, which offers practical guidance for method development in peptide-based therapeutics.

• Scale-Up Of A Transient rAAV Production Process

  11/3/2025

  Scalable rAAV production is achievable with a transient cell line and optimized bioreactor setup, delivering high titers and reduced impurities, now validated at 200 L scale for commercial readiness.